A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)

Nature Genetics

Volumn 42, Issue 12, 2010, Pages 1126-1130

  Enciso Mora, Victor ^a   Broderick, Peter ^a   Ma, Yussanne ^a   Jarrett, Ruth F ^b   Hjalgrim, Henrik ^c   Hemminki, Kari ^d,e   Van Den Berg, Anke ^f   Olver, Bianca ^a   Lloyd, Amy ^a   Dobbins, Sara E ^a   Lightfoot, Tracy ^g   Van Leeuwen, Flora E ^h   Försti, Asta ^d   Diepstra, Arjan ^e   Broeks, Annegien ^h   Vijayakrishnan, Jayaram ^a   Shield, Lesley ^b   Lake, Annette ^b   Montgomery, Dorothy ^b   Roman, Eve ^g   Engert, Andreas ⁱ   Von Strandmann, Elke Pogge ⁱ   Reiners, Katrin S ⁱ   Nolte, Ilja M ^f   Smedby, Karin E ^j   Adami, Hans Olov ^k,l   Russell, Nicola S ^h   Glimelius, Bengt ^k,m   Hamilton Dutoit, Stephen ⁿ   De Bruin, Marieke ^h   Ryder, Lars P ^o   Molin, Daniel ^m   Sorensen, Karina Meden ^c   Chang, Ellen T ^p,q   Taylor, Malcolm ^r   Cooke, Rosie ^a   Hofstra, Robert ^f   Westers, Helga ^f   Van Wezel, Tom ^s   Van Eijk, Ronald ^s   Ashworth, Alan ^a   Rostgaard, Klaus ^c   Melbye, Mads ^c   Swerdlow, Anthony J ^p   Houlston, Richard S ^a   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c STATENS SERUM INSTITUT   (Denmark)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e LUND UNIVERSITY   (Sweden)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g UNIVERSITY OF YORK   (United Kingdom)

^h ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

ⁱ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k KAROLINSKA INSTITUTE   (Sweden)

^l HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^m UPPSALA UNIVERSITY   (Sweden)

ⁿ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^o Rigshospitalet   (Denmark)

^p CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^q STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r UNIVERSITY OF MANCHESTER   (United Kingdom)

^s LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR REL;

ADULT; ARTICLE; CARCINOGENESIS; CHROMOSOME 10P; CHROMOSOME 8Q; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOME; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PRIORITY JOURNAL;

ADULT; CHROMOSOMES, HUMAN; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; GATA3 TRANSCRIPTION FACTOR; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; HODGKIN DISEASE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-REL; RECOMBINATION, GENETIC;

EID: 78649471895     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.696     Document Type: Article

References (67)

1. Kuppers, R. The biology of Hodgkin's lymphoma. Nat. Rev. Cancer 9, 15-27 (2009)
2. Swerdlow, A.J. Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma. Eur. J. Nucl. Med. Mol. Imaging 30 Suppl 1, S3-S12 (2003).
3. Smith, A. et al. The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br. J. Haematol. 148, 739-753 (2010).
4. Kutok, J.L. & Wang, F. Spectrum of Epstein-Barr virus-associated diseases. Annu. Rev. Pathol. 1, 375-404 (2006).
5. Goldin, L.R. et al. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer 100, 1902-1908 (2004).
6. Amiel, J. Study of the leukocyte phenotypes in Hodgkin's disease. in Histocompatibility Testing (ed, Teraski, P.I.) (Munksgaard, Copenhagen, Denmark, 1967).
7. Klitz, W., Aldrich, C.L., Fildes, N., Horning, S.J. & Begovich, A.B. Localization of predisposition to Hodgkin disease in the HLA class II region. Am. J. Hum. Genet. 54, 497-505 (1994).
8. Oza, A.M. et al. A clinical and epidemiological study of human leukocyte antigen-DPB alleles in Hodgkin's disease. Cancer Res. 54, 5101-5105 (1994).
9. Hjalgrim, H. et al. HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma. Proc. Natl. Acad. Sci. USA 107, 6400-6405 (2010).
10. Niens, M. et al. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood 110, 3310-3315 (2007).
11. Risch, N. Assessing the role of HLA-linked and unlinked determinants of disease. Am. J. Hum. Genet. 40, 1-14 (1987).
12. Goldin, L.R. et al. A genome screen of families at high risk for Hodgkin lymphoma: evidence for a susceptibility gene on chromosome 4. J. Med. Genet. 42, 595-601 (2005).
13. Mack, T.M. et al. Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N. Engl. J. Med. 332, 413-418 (1995).
14. Power, C. & Elliott, J. Cohort profle: 1958 British birth cohort (National Child Development Study). Int. J. Epidemiol. 35, 34-41 (2006).
15. Clayton, D.G. et al. Population structure, differential bias and genomic control in a large-scale, case-control association study. Nat. Genet. 37, 1243-1246 (2005).
16. Price, A.L. et al. Principal components analysis corrects for stratifcation in genome-wide association studies. Nat. Genet. 38, 904-909 (2006).
17. Wellcome Trust Case-Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678 (2007).
18. Cabannes, E., Khan, G., Aillet, F., Jarrett, R.F. & Hay, R.T. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 18, 3063-3070 (1999).
19. Emmerich, F. et al. Overexpression of IκBα without inhibition of NF-κB activity and mutations in the IκBα gene in Reed-Sternberg cells. Blood 94, 3129-3134 (1999).
20. Schmitz, R. et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J. Exp. Med. 206, 981-989 (2009).
21. Barth, T.F. et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood 101, 3681-3686 (2003).
22. Joos, S. et al. Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int. J. Cancer 103, 489-495 (2003).
23. Martin-Subero, J.I. et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 99, 1474-1477 (2002).
24. Villeneuve, L., Rassart, E., Jolicoeur, P., Graham, M. & Adams, J.M. Proviral integration site Mis-1 in rat thymomas corresponds to the pvt-1 translocation breakpoint in murine plasmacytomas. Mol. Cell. Biol. 6, 1834-1837 (1986).
25. Beck-Engeser, G.B. et al. Pvt1-encoded microRNAs in oncogenesis. Retrovirology 5, 4 (2008).
26. Bakkus, M.H., Brakel-van Peer, K.M., Michiels, J.J., van 't Veer, M.B. & Benner, R. Amplifcation of the c-myc and the pvt-like region in human multiple myeloma. Oncogene 5, 1359-1364 (1990).
27. Huppi, K., Siwarski, D., Skurla, R., Klinman, D. & Mushinski, J.F. Pvt-1 transcripts are found in normal tissues and are altered by reciprocal(6;15) translocations in mouse plasmacytomas. Proc. Natl. Acad. Sci. USA 87, 6964-6968 (1990).
28. Storlazzi, C.T. et al. Identifcation of a commonly amplifed 4.3 Mb region with overexpression of C8FW, but not MYC in MYC-containing double minutes in myeloid malignancies. Hum. Mol. Genet. 13, 1479-1485 (2004).
29. Crowther-Swanepoel, D. et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 infuence chronic lymphocytic leukemia risk. Nat. Genet. 42, 132-136 (2010).
30. Gudmundsson, J. et al. Genome-wide association study identifes a second prostate cancer susceptibility variant at 8q24. Nat. Genet. 39, 631-637 (2007).
31. Easton, D.F. et al. Genome-wide association study identifes novel breast cancer susceptibility loci. Nature 447, 1087-1093 (2007).
32. Tomlinson, I. et al. A genome-wide association scan of tag SNPs identifes a susceptibility variant for colorectal cancer at 8q24.21. Nat. Genet. 39, 984-988 (2007).
33. Yeager, M. et al. Genome-wide association study of prostate cancer identifes a second risk locus at 8q24. Nat. Genet. 39, 645-649 (2007).
34. Amundadottir, L.T. et al. A common variant associated with prostate cancer in European and African populations. Nat. Genet. 38, 652-658 (2006).
35. Kiemeney, L.A. et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat. Genet. 40, 1307-1312 (2008).
36. Tuupanen, S. et al. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat. Genet. 41, 885-890 (2009).
37. Pomerantz, M.M. et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat. Genet. 41, 882-884 (2009).
38. Faumont, N. et al. c-Myc and Rel/NF-κB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells. J. Virol. 83, 5014-5027 (2009).
39. Ho, I.C., Tai, T.S. & Pai, S.Y. GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. Nat. Rev. Immunol. 9, 125-135 (2009).
40. Li, J., Qian, C.N. & Zeng, Y.X. Regulatory T cells and EBV associated malignancies. Int. Immunopharmacol. 9, 590-592 (2009).
41. Atayar, C. et al. Expression of the T-cell transcription factors, GATA-3 and T-bet, in the neoplastic cells of Hodgkin lymphomas. Am. J. Pathol. 166, 127-134 (2005).
42. La Rosa, F.A., Pierce, J.W. & Sonenshein, G.E. Differential regulation of the c-myc oncogene promoter by the NF-κB rel family of transcription factors. Mol. Cell. Biol. 14, 1039-1044 (1994).
43. Maurice, D., Hooper, J., Lang, G. & Weston, K. c-Myb regulates lineage choice in developing thymocytes via its target gene Gata3. EMBO J. 26, 3629-3640 (2007).
44. Papaemmanuil, E. et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat. Genet. 41, 1006-1010 (2009).
45. Jundt, F. et al. Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood 99, 3060-3062 (2002).
46. Hjalgrim, H. & Engels, E.A. Infectious aetiology of Hodgkin and non-Hodgkin lymphomas: a review of the epidemiological evidence. J. Intern. Med. 264, 537-548 (2008).
47. Stranger, B.E. et al. Genome-wide associations of gene expression variation in humans. PLoS Genet. 1, e78 (2005).
48. Stranger, B.E. et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315, 848-853 (2007).
49. Alexander, F.E. et al. An epidemiologic study of index and family infectious mononucleosis and adult Hodgkin's disease (HD): evidence for a specifc association with EBV+ve HD in young adults. Int. J. Cancer 107, 298-302 (2003).
50. Jarrett, R.F. et al. The Scotland and Newcastle epidemiological study of Hodgkin's disease: impact of histopathological review and EBV status on incidence estimates. J. Clin. Pathol. 56, 811-816 (2003).
51. Willett, E.V., O'Connor, S., Smith, A.G. & Roman, E. Does smoking or alcohol modify the risk of Epstein-Barr virus-positive or -negative Hodgkin lymphoma? Epidemiology 18, 130-136 (2007).
52. Penegar, S. et al. National study of colorectal cancer genetics. Br. J. Cancer 97, 1305-1309 (2007).
53. Hjalgrim, H. et al. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res. 67, 2382-2388 (2007). (Pubitemid 46424260)
54. Smedby, K.E. et al. Ultraviolet radiation exposure and risk of malignant lymphomas. J. Natl. Cancer Inst. 97, 199-209 (2005).
55. Sorensen, K.M. et al. Whole genome amplifcation on DNA from flter paper blood spot samples: an evaluation of selected systems. Genet. Test. 11, 65-71 (2007).
56. van Leeuwen, F.E. et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J. Natl. Cancer Inst. 95, 971-980 (2003).
57. Broeks, A. et al. Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations. Int. J. Radiat. Biol. 76, 693-698 (2000).
58. De Bruin, M.L. et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J. Clin. Oncol. 27, 4239-4246 (2009).
59. Lake, A. et al. Mutations of NFKBIA, encoding IκBα, are a recurrent fnding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases. Int. J. Cancer 125, 1334-1342 (2009).
60. Pettiti, D. Meta-analysis Decision Analysis and Cost-Effectiveness Analysis (Oxford University Press, Oxford, New York, 1994).
61. Higgins, J.P. & Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539-1558 (2002).
62. Myers, S., Bottolo, L., Freeman, C., McVean, G. & Donnelly, P. A fne-scale map of recombination rates and hotspots across the human genome. Science 310, 321-324 (2005).
63. Gabriel, S.B. et al. The structure of haplotype blocks in the human genome. Science 296, 2225-2229 (2002).
64. Matys, V. et al. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res. 34, D108-D110 (2006).
65. Ferretti, V. et al. PReMod: a database of genome-wide mammalian cis-regulatory module predictions. Nucleic Acids Res. 35, D122-D126 (2007).
66. Hallikas, O. et al. Genome-wide prediction of mammalian enhancers based on analysis of transcription-factor binding affnity. Cell 124, 47-59 (2006).
67. Cuzick, J. Wilcoxon-type test for trend. Stat. Med. 4, 87-90 (1985).